The invention is directed to formulations of lipophilic Amyloid &bgr；eta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously wherein the lipophilic Amyloid &bgr；eta ligand stilbene based derivative is a 19F or 18F-labeled radiopharmaceutical thereof. Further, the invention is directed to a method for sterile filtration of said suitable formulation.
